BR112019000690A2 - composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide - Google Patents

composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide

Info

Publication number
BR112019000690A2
BR112019000690A2 BR112019000690-7A BR112019000690A BR112019000690A2 BR 112019000690 A2 BR112019000690 A2 BR 112019000690A2 BR 112019000690 A BR112019000690 A BR 112019000690A BR 112019000690 A2 BR112019000690 A2 BR 112019000690A2
Authority
BR
Brazil
Prior art keywords
disorder
disease
treating
dosage form
oral dosage
Prior art date
Application number
BR112019000690-7A
Other languages
English (en)
Inventor
Friedman Doron
Original Assignee
Icdpharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icdpharma Ltd filed Critical Icdpharma Ltd
Publication of BR112019000690A2 publication Critical patent/BR112019000690A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a presente invenção provê composições e formulações de canabinóide em altas doses e altas concentrações, auto-emulsificantes, para melhorar a administração de canabinóides e extratos de maconha padronizados aos pacientes.
BR112019000690-7A 2016-07-14 2017-07-12 composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide BR112019000690A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL246790 2016-07-14
IL246790A IL246790A0 (en) 2016-07-14 2016-07-14 Self-dissolving compounds of cannabinoids
PCT/IL2017/050793 WO2018011808A1 (en) 2016-07-14 2017-07-12 Self-emulsifying compositions of cannabinoids

Publications (1)

Publication Number Publication Date
BR112019000690A2 true BR112019000690A2 (pt) 2019-04-24

Family

ID=60952025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000690-7A BR112019000690A2 (pt) 2016-07-14 2017-07-12 composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide

Country Status (11)

Country Link
US (2) US10898463B2 (pt)
EP (1) EP3484468A4 (pt)
JP (1) JP2019523296A (pt)
KR (1) KR20190029660A (pt)
CN (1) CN109952098A (pt)
AU (1) AU2017296180A1 (pt)
BR (1) BR112019000690A2 (pt)
CA (1) CA3030535A1 (pt)
IL (2) IL246790A0 (pt)
MX (1) MX2019000427A (pt)
WO (1) WO2018011808A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
EP3478307A4 (en) 2016-06-29 2020-02-26 Cannscience Innovations Inc. DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING
WO2018023164A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
BR112019003815A2 (pt) * 2016-08-29 2019-05-21 Canopy Growth Corporation composições solúveis em água compreendendo canabinoides purificados
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
JP2020509081A (ja) * 2017-02-15 2020-03-26 モレキュラー インフュージョンズ、エルエルシー 製剤
CA3065563C (en) * 2017-06-19 2023-06-13 Zelda Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
EP4356965A2 (en) * 2017-07-14 2024-04-24 5071, Inc. Cannabinoid compositions and methods of preparation thereof
WO2019136351A1 (en) * 2018-01-05 2019-07-11 Altus Labs, Llc Personal care compositions
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
WO2019159174A1 (en) * 2018-02-16 2019-08-22 Icdpharma Ltd. Colonic delivery of cannabinoids in solid solution compositions
US20190254988A1 (en) * 2018-02-16 2019-08-22 Botanical Process Solutions LLC Use of non crystalline terpene alcohols for the inhibition of crystallization of cannabinoids
WO2019175290A1 (en) * 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US20230110830A1 (en) 2018-04-09 2023-04-13 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019222459A1 (en) * 2018-05-18 2019-11-21 Diverse Biotech, Inc. Cannabinoid preparations and therapeutic uses
WO2019240581A1 (en) * 2018-06-14 2019-12-19 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
US20200138772A1 (en) * 2018-07-09 2020-05-07 Volker Berl Stabilized formulations of cannabinoid compositions
WO2020024009A1 (en) * 2018-07-31 2020-02-06 AusCann Group Holdings Ltd "solid self-emulsifying pharmaceutical compositions"
BR112021003151A2 (pt) * 2018-08-20 2021-05-11 Hexo Operations Inc. produto infundido com canábis com experiência de usuário de perfil de canabinoide controlado
US20210315818A1 (en) * 2018-08-20 2021-10-14 Hexo Operations Inc. Cannabinoid based emulsion systems for infused non-aqueous compositions
US20210236575A1 (en) * 2018-08-27 2021-08-05 Emerald Health Therapeutics Canada Inc. Therapeutic combinations of cannabinoids with curcumin
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP3876918A4 (en) * 2018-11-09 2022-08-10 Cronos Group Inc. LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE
CN109528649B (zh) * 2019-01-15 2021-06-29 北京远大九和药业有限公司 一种萜烯类药物组合物自乳化口服制剂及制备方法、应用
GB2581517A (en) * 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2020212976A1 (en) * 2019-04-18 2020-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Self-emulsifying drug delivery systems for delivery of lipophilic compounds
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
WO2020260956A2 (en) * 2019-05-15 2020-12-30 Fresh Cut Development, Llc Self-emulsifying cannabidiol formulations
US20210038558A1 (en) * 2019-08-07 2021-02-11 Orochem Technologies Inc. Water-soluble cannabinoids
JP2022546814A (ja) * 2019-09-06 2022-11-09 クイックシルバー サイエンティフィック インコーポレイテッド カンナビス抽出物およびテルペンのためのマイクロエマルジョン送達系
EP4028059A4 (en) * 2019-09-09 2023-05-24 Cardiol Therapeutics Inc. STABLE MEDICINAL COMPOSITIONS OF CANNABIDIOL
EP4009815A4 (en) * 2019-09-12 2023-09-06 Nulixir Inc. CORE-SHELL PARTICLES WITH CONTROLLED RELEASE AND SUSPENSIONS CONTAINING SAME
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021084527A1 (en) * 2019-10-28 2021-05-06 Israel Plastics and Rubber Center Ltd. Self-emulsifying cannabis extract
EP4054530A1 (en) 2019-11-04 2022-09-14 Landrace Bioscience Inc. Self-emulsifying cannabinoid formulation and method
JP2023500372A (ja) * 2019-11-08 2023-01-05 ヴェラ・バイオサイエンス・インコーポレイテッド 女性の性機能を強化するかまたは女性の性障害を治療するための末梢作用性カンナビジオール（ｃｂｄ）含有組成物およびその使用
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
US20210299081A1 (en) * 2020-03-25 2021-09-30 Molecular Infusions, Llc Solid cannabinoid formulation for oral administration
WO2021202413A1 (en) * 2020-03-30 2021-10-07 Ojai Energetics Pbc Systems, methods, and compositions for infections
FR3110427B1 (fr) * 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
WO2021252957A1 (en) * 2020-06-11 2021-12-16 Test Kitchens, Inc. Cannabinoid complexes and methods of making and using them
US20210401746A1 (en) * 2020-06-26 2021-12-30 cbdMD, Inc. Stable cannabinoid compositions
EP4196112A1 (en) * 2020-08-14 2023-06-21 Capheads LLC Dosing capsule made from cannabis-derived resin and methods of making the same
CN112755006A (zh) * 2020-08-17 2021-05-07 深圳市泰力生物医药有限公司 大麻二酚膜制剂及其用途
WO2022087171A1 (en) * 2020-10-20 2022-04-28 Tellus Brands, Llc Formulations for cannabinoid permeation enhancement
WO2022104245A2 (en) * 2020-11-16 2022-05-19 SYNERGY LIFE SCIENCE, Inc. Cannabinoid emulsifier
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂
CN113209052B (zh) * 2021-03-16 2022-02-15 深圳市泰力生物医药有限公司 大麻二酚自纳米乳口颊膜制剂及其制备方法和用途
WO2023287891A1 (en) * 2021-07-13 2023-01-19 Demetrix, Inc. Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions
US20230075007A1 (en) * 2021-08-09 2023-03-09 Impact Naturals, Inc. Pharmaceutical formulations of cannabidiol
WO2023129153A1 (en) * 2021-12-29 2023-07-06 Pegasus Laboratories, Inc. Granular composition providing water dispersible cannabinoids and methods of making the same
AU2023212130A1 (en) * 2022-01-27 2024-05-23 DEFINED RESEARCH, Inc. A cannabidiol (cbd) and terpene formulation that increases restorative sleep in humans
US20230338329A1 (en) * 2022-04-22 2023-10-26 Douglas Gore Cannabinoid emulsion composition and method of manufacturing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2012033478A1 (en) * 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US9095563B2 (en) 2013-09-26 2015-08-04 Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
AU2014347807A1 (en) 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
EP3423033A4 (en) 2016-03-04 2020-01-01 Sharon Anavi-Goffer SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS

Also Published As

Publication number Publication date
US10898463B2 (en) 2021-01-26
EP3484468A1 (en) 2019-05-22
JP2019523296A (ja) 2019-08-22
US20210228534A1 (en) 2021-07-29
WO2018011808A1 (en) 2018-01-18
KR20190029660A (ko) 2019-03-20
EP3484468A4 (en) 2020-03-25
MX2019000427A (es) 2019-06-10
IL264210A (en) 2019-02-28
CN109952098A (zh) 2019-06-28
US20190298683A1 (en) 2019-10-03
AU2017296180A1 (en) 2019-01-31
CA3030535A1 (en) 2018-01-18
IL246790A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
BR112019000690A2 (pt) composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide
BR112019001794A2 (pt) composição de cannabis
CL2019000268A1 (es) Composición de cannabis.
BR112019006106A2 (pt) formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio.
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CO2018013654A2 (es) Composiciones nasales de cannabidiol
BR112018076114A2 (pt) composições tópicas de apremilast
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
BR112019001852A2 (pt) composição de cannabis
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
BR112018008186A2 (pt) métodos que utilizam proteína de soro de leite para melhorar ou manter a qualidade muscular
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112018007958A2 (pt) composições e métodos que usam um polifenol para a saúde musculoesquelética
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
CL2019000625A1 (es) Combinación de agonistas de fxr.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]